Health ❯Healthcare ❯Medical Treatments

Neurology

Alzheimer's Disease Parkinson's Disease Cognitive Disorders

EU Approves First Alzheimer's Drug Targeting Disease Progression

Lecanemab, designed to slow early-stage cognitive decline, faces stringent eligibility criteria and logistical hurdles before rollout.

EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

FDA Approves Vyalev for Advanced Parkinson's Disease Treatment

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety